- Home
- MYN vs EBS Comparison
MYN vs EBS Comparison
Compare MYN & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYN
- EBS
- Stock Information
- Founded
- MYN 1992
- EBS 1998
- Country
- MYN United States
- EBS United States
- Employees
- MYN N/A
- EBS N/A
- Industry
- MYN Finance Companies
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- MYN Finance
- EBS Health Care
- Exchange
- MYN Nasdaq
- EBS Nasdaq
- Market Cap
- MYN 358.2M
- EBS 359.3M
- IPO Year
- MYN N/A
- EBS 2006
- Fundamental
- Price
- MYN $9.59
- EBS $7.56
- Analyst Decision
- MYN
- EBS Strong Buy
- Analyst Count
- MYN 0
- EBS 3
- Target Price
- MYN N/A
- EBS $14.33
- AVG Volume (30 Days)
- MYN 86.0K
- EBS 1.2M
- Earning Date
- MYN 01-01-0001
- EBS 11-05-2025
- Dividend Yield
- MYN 4.12%
- EBS N/A
- EPS Growth
- MYN N/A
- EBS N/A
- EPS
- MYN N/A
- EBS 2.53
- Revenue
- MYN N/A
- EBS $851,600,000.00
- Revenue This Year
- MYN N/A
- EBS N/A
- Revenue Next Year
- MYN N/A
- EBS $19.24
- P/E Ratio
- MYN N/A
- EBS $3.00
- Revenue Growth
- MYN N/A
- EBS N/A
- 52 Week Low
- MYN $8.47
- EBS $4.02
- 52 Week High
- MYN $10.62
- EBS $12.73
- Technical
- Relative Strength Index (RSI)
- MYN 69.24
- EBS 41.04
- Support Level
- MYN $9.20
- EBS $8.16
- Resistance Level
- MYN $9.33
- EBS $8.62
- Average True Range (ATR)
- MYN 0.09
- EBS 0.36
- MACD
- MYN 0.03
- EBS -0.23
- Stochastic Oscillator
- MYN 93.48
- EBS 4.29
About MYN Blackrock MuniYield New York Quality Fund Inc.Common Stock
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.